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Abstract
Severe Acute Respiratory Syndrome caused substantial morbidity and mortality during the 2002–2003 epidemic. Many of
the features of the human disease are duplicated in BALB/c mice infected with a mouse-adapted version of the virus (MA15),
which develop respiratory disease with high morbidity and mortality. Here, we show that severe disease is correlated with
slow kinetics of virus clearance and delayed activation and transit of respiratory dendritic cells (rDC) to the draining lymph
nodes (DLN) with a consequent deficient virus-specific T cell response. All of these defects are corrected when mice are
treated with liposomes containing clodronate, which deplete alveolar macrophages (AM). Inhibitory AMs are believed to
prevent the development of immune responses to environmental antigens and allergic responses by interacting with lung
dendritic cells and T cells. The inhibitory effects of AM can also be nullified if mice or AMs are pretreated with poly I:C, which
directly activate AMs and rDCs through toll-like receptors 3 (TLR3). Further, adoptive transfer of activated but not resting
bone marrow–derived dendritic cells (BMDC) protect mice from lethal MA15 infection. These results may be relevant for
SARS in humans, which is also characterized by prolonged virus persistence and delayed development of a SARS-CoV-
specific immune response in individuals with severe disease.
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Introduction
The lung is exposed to many challenges, both environmental
and pathogenic. Defense of this portal must be tightly regulated so
that appropriate immune responses to pathogens are mounted but
responses to innocuous antigens are minimized. Alveolar macro-
phages (AM) play a central role in maintaining this immunological
homeostasis [1,2,3]. In the lung, resident AMs are continuously
encountering inhaled substances due to their exposed position in
the alveolar lumen, but they are kept in a quiescent state. They
function poorly as accessory cells for in vitro T cell activation [4,5]
and in many situations actively suppress the induction of adaptive
immunity through their effects on alveolar and interstitial DCs and
T cells [6,7,8]. In vivo elimination of alveolar macrophages using
clodronate-filled liposomes (CL) leads to overt inflammatory
reactions to otherwise harmless particulate and soluble antigens
[9]. Alveolar macrophages adhere closely to alveolar epithelial
cells (AECs) at the alveolar wall and are separated by a distance of
only 0.2–0.5 mm from rDCs [6]. In macrophage-depleted mice,
DCs have enhanced antigen-presenting function [6]. It has been
estimated that the pool of murine alveolar macrophages can
process up to 10
9 intratracheally injected bacteria before there is
‘‘spillover’’ of bacteria to DCs and before adaptive immunity is
induced [10].
Although the importance of such mechanisms to control
undesirable responses to inert environmental antigens is self-
evident, it is also axiomatic that countermeasures must be
available to allow reversal of this inhibition after challenge with
inhaled pathogenic (notably microbial) antigens. During infection
with respiratory pathogens, such as influenza virus, antigen is
acquired by respiratory dendritic cells (rDCs) and these cells must
be sufficiently activated to overcome anti-inflammatory factors in
the lungs. These rDCs then migrate to the lung draining lymph
nodes (DLN) to initiate an antiviral CD8 T cell response [11,12].
After the interaction of naive T cells with such antigen-bearing
DCs, CD8 and likely CD4 T cells undergo activation and division
in the DLNs and migrate into the lungs to eliminate virus-infected
cells, leading to resolution of the infection [13,14,15]. Recently, a
secondary peripheral interaction of CD8 T cells with antigen-
bearing rDCs in the lung was found important for effective
antiviral immunity [16]. Overall rDC activation is a prerequisite
for initiation and maintenance of the immune response.
Patients with the Severe Acute Respiratory Syndrome (SARS),
caused by a novel coronavirus (SARS-CoV), developed mild to
fatal pulmonary disease, with a mortality incidence of 10% [17].
Patients with worse outcomes generally exhibited a more
protracted clinical course, characterized by the development of
Adult Respiratory Distress Syndrome (ARDS), as well as
lymphopenia, neutrophilia and prolonged cytokine production
[17,18,19,20]. Virus could be detected in nasopharyngeal aspirate
and feces for as long as 21 days after disease onset [19,21].
Delayed virus clearance may have resulted from suboptimal T and
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detected in patients with severe disease [17,18,19,20]. Numerous
studies demonstrated that SARS-CoV infection fails to activate
macrophages and dendritic cells. Although these cells can be
infected, they are functionally impaired: antiviral cytokines such as
type I interferon were not expressed and endocytic capacity
(antigen capture) was compromised ([22,23,24,25,26,27,28] and
reviewed in [29]). These unusual findings raised the possibility that
initial infection with the virus resulted in delayed or suboptimal
activation of the innate immune system. Inefficient activation of
rDCs might be unable to counter the potent anti-inflammatory
factors that are normally present in the lung, resulting in both a
deficient T cell response and delayed kinetics of virus clearance.
Recently, rodent-adapted strains of SARS-CoV, which cause
mild to fatal respiratory disease, were developed in several
laboratories [30,31]. Here, we demonstrate that lethal disease in
mice infected with a mouse-adapted strain of SARS-CoV (MA15)
can be prevented if AMs with anti-inflammatory properties are
depleted from the lung prior to infection. Treatment with toll-like
receptor (TLR) agonists to activate rDCs or transfer of activated
bone marrow-derived dendritic cells (BMDC) also prevents a
lethal outcome. Together, these results demonstrate that SARS-
CoV, by inefficiently activating the immune system, uses a novel
mechanism to evade immune recognition.
Results
AM depletion before inoculation protected BALB/c mice
from lethal MA15 infection
SARS-CoV infection results in inefficient activation of macro-
phages and DCs in vitro [22,23,24,25,26,27,28] and slow virus
clearance and a prolonged clinical course in humans [17,18,19].
Similarly, MA15 infection in vitro did not result in upregulation of
CD86 on AM (Fig. S2, Gating shown in Fig. S1 A). To determine
whether inhibitory AMs play a role in MA15-mediated severe lung
disease, we depleted these cells by intranasal administration of
clodronate liposomes (CL). CL are useful for depletion of AM, and
to a lesser extent, alveolar/airway DCs [9], but intranasal
administration does not affect the level of circulating macrophages
[32]. As a control, we treated mice with PBS as described
previously [33].
BALB/c mice were treated with 75 ml of CL or PBS intranasally
(i.n.) and total lung cells were harvested after enzymatic digestion.
After 24 h, there was a decrease of AMs (CD11c
+CD11b
2siglec
F
+ [34]) in the lung, both in frequency (.70%) and absolute
number (from 5–6610
4 to 1–2610
4 cells/lung), in CL, but not
PBS-treated mice (Fig. S3 A and B). By 48 h, approximately 90%
of AMs in the lung were depleted (Fig. S3 A and B).
To determine whether there was a change in clinical disease
after AM depletion, BALB/c mice were treated with 75 mlo fC L
and infected i.n. with 3610
4 PFU of MA15 virus. Mice were
monitored daily for weight loss and mortality. At this virus dosage,
control mice lost more than 20% of their body weight and 60%–
70% of them died (Fig. 1 A), generally from day 6 to day 8 post
infection (p.i.). Depletion of AM before inoculation (at day 21 and
day 22) completely protected mice from this lethal infection and
animals rapidly regained their body weight (Fig. 1 A). AM
depletion at day 2 p.i. was not protective and may have resulted in
more severe disease, as observed also in influenza A virus-infected
mice [16]. Of note, 6 week old C57Bl/6 mice are resistant to
MA15 infection and treatment at day 21 or 2 with clodronate had
no effect on the clinical course in these mice (data not shown).
Clodronate treatment resulted in enhanced kinetics of virus
clearance, with virus cleared from all treated but not control
BALB/c mice by day 7 p.i. (Fig. 1 B). We next examined lung
sections for changes in histology. There were no histological
differences in the lungs between CL-treated and control mice at
day 0, indicating that depletion of AMs did not result in significant
inflammatory cell recruitment to the lung. From day 2 p.i., PBS-
treated mice developed a rapidly progressive interstitial pneumo-
nia with extensive edema and damage to bronchiolar and alveolar
epithelial cells (Fig. 1 C). Inflammatory infiltrates were consistently
identified from days 2-to 6 p.i. CL-treated mice had a much better
outcome with less destruction of the pulmonary architecture, but
extensive alveolar, interstitial and perivascular inflammatory cell
infiltration (Fig. 1 C, day 4 and day 6). Total lung cell numbers are
shown in Fig. 2 A. Clodronate treatment, by removing AM, also
altered the inflammatory milieu of the lungs. As a consequence,
levels of pro-inflammatory cytokines and chemokines, such as IL-
1b, Il-6, IL-12, CCL2 and CCL3 increased within 24 hours of CL,
but not PBS treatment, prior to virus infection. By day 2 p.i., levels
of these cytokines were generally similar in CL and PBS-treated
mice, consistent with the notion that a delayed, and possibly
dysregulated, immune response contributed to severe disease in
control mice (Table S1).
AM depletion enhanced rDC activation, migration and
recruitment
Infection with respiratory viruses such as influenza A virus and
respiratory syncytial virus (RSV) results in recruitment of
CD11c
+MHC II
+ DCs to the lung [12,35,36,37]. Unlike these
infections, recruitment of inflammatory cells, including DCs, to the
lung is impaired in MA15-infected mice (Fig. 2 A). The total lung
cell number increased slightly, but there was no appreciable change
in numbers of the respiratory dendritic cells (rDC) in control mice.
Clodronate treatment resulted in enhancement of inflammatory cell
recruitment to the lung (Fig. 1 C and 2 A), with a nearly tenfold
increase in numbers of rDCs within 6 days (Fig. 2 A). For these
experiments, we distinguished two populations of rDCs: alveolar/
airway dendritic cells (aDC: CD11c
+CC11b
2MHC II
+)a n d
interstitial dendritic cells (iDC: CD11c
+CD11b
+MHC II
+) using
the gating strategy shown in Fig. S1. By day 4 p.i., the frequencies of
MHC II
high/CD86
+ and MHC II
high/CD40
+ aDC and iDC
Author Summary
Severe Acute Respiratory Syndrome (SARS) occurred in
human populations in 2002–2003 and was caused by a
novel coronavirus (CoV). Human SARS was characterized
by prolonged virus excretion, lymphopenia and delayed
adaptive immune responses in patients with severe
disease. Recently, small animal models have been devel-
oped that mimic some of the features of the human
disease. Specifically, BALB/c mice infected with mouse-
adapted SARS-CoV develop severe respiratory disease.
Here, we show that the T cell response is defective in these
mice and that this results from inefficient activation of the
initial immune response to the virus. This defect can be
corrected by several treatments, including depletion of
inhibitory macrophages from the lungs and direct
activation of respiratory dendritic cells, important in
initiating the immune response or transfer of activated
dendritic cells prior to infection. All of these modalities
result in improved initiation of the immune response and
an enhanced anti-virus T cell response. Inefficient activa-
tion of the immune response may play a role in human
SARS, and our results suggest possible strategies that
might be used to develop novel anti-viral therapies.
Macrophages and DCs in SARS-CoV Infection
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iDC and not at all on aDC in PBS-treated mice Over the next few
days aDCs and iDCs remain activated in CL-treated mice but
mostly returned to a baseline state in control mice (Fig. 2 B and C).
Concomitant with this recruitment and activation of rDCs, we also
observed enhanced rDC migration to draining lymph nodes (DLN),
using a tracking method in which rDCs are labeled in the lung by
i.n. inoculation of carboxyfluorescein diacetate succinimidyl ester
(CFSE) (see Materials and Methods and Fig. S1 B for gating) [12].
In all mice, rDC migration to the DLNs peaked at 18 h p.i., but
migration was accelerated by treatment with clodronate. After
48 hours the frequency and number of CFSE
+ rDCs in the DLNs
decreased suggesting that the first 48 h p.i. were most important
period for rDC migration. There was also a two-three fold increase
in total cell numbers in the DLNs (Fig. 2 D). Collectively, these
results show that DCs remained activated for longer times in the
Figure 1. Effect of CL treatment on weight loss, mortality, histological changes and virus titers in MA15-infected BALB/c mice. (A)
BALB/c mice (6–8 weeks old) were treated with 75 ml CL or PBS at before or after intranasal infection with 3610
4 PFU MA15 virus in 25 ml DMEM.
Weight loss and mortality were monitored daily. n=12 mice in PBS group; 20 mice in CL group. (B) For virus titers, lungs were homogenized and
titeted on Vero E6 cells. Viral titers are expressed as PFU/g tissue. n=4 mice/group/time point. *P values of ,0.05. (C) BALB/c mice were treated with
CL or PBS 18–24 h prior to infection with 3610
4 PFU MA15 virus. Lungs were removed at the indicated time points p.i.. Lungs were fixed in zinc
formalin, and paraffin embedded. Sections were stained with hematoxylin and eosin.
doi:10.1371/journal.ppat.1000636.g001
Macrophages and DCs in SARS-CoV Infection
PLoS Pathogens | www.plospathogens.org 3 October 2009 | Volume 5 | Issue 10 | e1000636Figure 2. Respiratory dendritic cell recruitment, migration and activation in MA15-infected mice after CL or PBS treatment. Mice
were treated with CL or PBS 18–24 h prior to infection with 3610
4 PFU MA15. Lungs were harvested at the indicated time points, and after enzyme
digestion, single cell suspensions were acquired. Cells were stained for CD11c, MHC class II, CD11b, CD86 and CD40 expression. Total numbers of
inflammatory cells and of CD11c
+MHC II
+ rDC in the lung are shown (A). CD86 and CD40 expression was measured on aDCs (CD11c
+CD11b
2MHC II
+)
and iDCs (CD11c
+CD11b
+MHC II
+). An example of CD86 expression at day 6 p.i. (B) and a summary of MHC
highCD86
+ or MHC
highCD40
+ expression
frequencies (C) are shown. Data are representative of two independent experiments and are the mean values6SEM (n=7–8 mice/group/time point).
(D) Mice were treated with CL or PBS 18–24 h before i.n. inoculation of 50 ml 8 mM CFSE. 6 h after CFSE instillation, mice were infected with 3610
4
PFU MA15 virus or were mock infected. At the indicated time points p.i., single cell suspensions were prepared from lung DLNs and gated for CD11c
expression by flow cytometry. The values represent the percentage of CFSE
+ cells within the CD11c
+ DC population per LN. n=4 mice/group/time
point. *P values of ,0.05.
doi:10.1371/journal.ppat.1000636.g002
Macrophages and DCs in SARS-CoV Infection
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treatment. A consequence of the increase in both numbers of rDCs
and the frequency that was activated was a 30–50 fold increase in
total activated DCs in the lung.
AM depletion before infection results in enhanced T cell
responses
Since enhanced rDC migration to DLNs is predicted to result in
enhanced virus-specific T cell responses, we next examined the
magnitude of total and MA15-specific T cell responses in the lungs
of CL treated and control infected mice. Clodronate treatment
resulted in greater numbers of activated CD8 and CD4 T cells in
the MA15-infected lung (Fig. S4 A and B), compared to PBS
treatment, as determined by CD43 (clone 1B11) expression. The
latter is upregulated on activated effector T cells [38,39].
To assess effects on MA15-specific T cell responses, we initially
identified a set of H-2
d-restricted virus-specific CD4 and CD8 T
cells epitopes using lung derived cells harvested from infected mice
and a peptide library covering all four structural proteins (S, N, M,
E) of SARS-CoV. Several IFN-c inducing CD8 and CD4 epitopes
in the spike (S) and nucleocapsid (N) proteins (S366–374, S521–
529, S1061–1071 and N353–370) were identified (manuscript in
preparation). Some of these epitopes were described previously,
but S521 and S1061 epitopes were newly discovered. Of note, all
other previously described H-2
d-restricted T cell epitopes were not
recognized by lung-derived T cells in our assays [40,41,42]. These
previous reports identified T cell epitopes using adenovirus vectors
or DNA constructs expressing single SARS-CoV proteins, or
isolated peptides. We speculate that the numbers of T cells
recognizing these previously described epitopes are present at very
low levels in infected mice compared to the immunodominant
epitopes that we identify, possibly because of differences in antigen
presentation between infected and immunized mice.
Using these epitopes, we found that AM-depleted mice
exhibited earlier and more robust virus-specific T cell responses,
as measured by intracellular cytokine staining (ICS) for IFN-c,
whereas control mice had almost no virus-specific T cell responses
at days 6 and 7 p.i. (Fig. 3 A and B). PBS-treated mice that
survived until day 8 p.i. mounted virus-specific T cell responses in
the lung, but at a level that was much less than observed in CL-
treated mice. We confirmed that these cells were functional using
in vivo cytotoxicity assays. Naı ¨ve splenocytes were costained with
PKH26 and CFSE, pulsed with MA15-specific CD8 T cell
peptides and adoptively transferred i.n. into mice 12 h before
harvest of total lung cells. Robust CD8 T cell cytotoxic responses
were observed in AM-depleted mice, with 40%–50% killing of
virus-specific targets. By comparison, only about 5% of target cells
were lysed in control mice (Fig. 3 C).
Alveolar macrophages are inhibitory in vivo and in vitro
Results thus far suggest that inhibitory macrophages are
dominant in MA15-infected lungs. In support of this, AM were
only transiently and slightly activated, as measured by CD86 and
CD40 expression, after infection with MA15 (Fig. 4 A). F4/80,
considered a marker for macrophage maturation and phagocytosis
[43], was present at lower levels on AMs harvested from
uninfected mice compared to macrophages isolated from other
sites (e.g., peritoneal macrophages [44], Fig. S5) and was not
upregulated after MA15 infection (Fig. 4 A). Further, surface levels
of CD200R, important in maintaining lung homeostasis, were
higher on AM than peritoneal macrophages [44] (Fig. S5) and
were not significantly downregulated after infection (Fig. 4 A),
indicating that AMs continued to be inhibitory even after the onset
of the infection. The number and frequency of AMs increased at
day 2 before returning to baseline by day 6 p.i. in control mice but,
as expected, remained low throughout the infection after
clodronate treatment, (Fig. 4 B).
Mature ‘‘resting’’ AMs are able to suppress in vitro proliferation
of homologous T-cells, and freshly isolated rDCs are poor antigen-
presenting cells, consistent with a suppressive state [6,45]. To
confirm the inhibitory properties of AMs, we isolated aDCs from
total lung cells and cultured them in vitro for 24 h in the presence
and absence of AMs. When cultured in the absence of AMs, aDC
upregulated expression of CD86, MHC II and CD40. Co-culture
with AMs prevented CD86 and MHC class II, and to a lesser
extent, CD40 upregulation (Fig. 4 C).
The prolonged presence of AMs in MA15-infected lungs
suggested that AMs not only inhibited rDCs activation, and
thereby delayed DC migration from lung to lymph nodes, but also
inhibited the function of anti-virus T cells in the lung. To examine
this possibility, we co-cultured AMs and T cells in vitro.
Concanavalin A (Con A) and soluble anti-CD3 (sCD3) antibody
treatment of lung cells resulted in proliferation of both CD4 and
CD8 T cells as measured by CFSE dilution. This proliferation was
almost completely inhibited by co-culture with purified AMs at a
ratio of 10:1 (10 T cells:1 AM) (Fig. 4 D). Of note, endogeous AMs
were removed from the lung cell preparations by incubation in a
tissue culture plate for 2 h (90% depletion, measured by flow
cytometry). In the absence of this prior incubation, no robust
proliferation was observed. To assess the effect of AM on virus-
specific T cells, we isolated CD8 T cells from MA15-infected, CL-
treated mouse lungs at day 8 p.i. using microbeads and stained
them with CFSE. Cells were then stimulated for 72 hours with
lung cells or splenocytes that were pulsed with three MA15-specific
CD8 T cell peptides (S366/S521/S1061) with or without AMs.
Although only about 30% of CD8 T cells were MA15-specific,
proliferation of CD8 T cells was clearly detected. When co-
cultured with AMs, CD8 T cell proliferation was totally inhibited
(Fig. 4 E). Thus, AMs inhibited both nonspecific and specific CD8
T cell proliferation. However, AM co-culture in vitro did not inhibit
IFN-c expression after stimulation with MA15-specific peptides
(Fig. S6 A), consistent with previous data, showing that AMs did
not inhibit IL-2 secretion by Con A-stimulated T cells [45].
Further, when AMs and T cells were separated by a transwell
during co-culture, no significant decrease of proliferation was
observed as measured by CFSE dilution (Fig. S6 B) suggesting that
AM inhibition of T cell proliferation required direct cell contact.
Poly I:C treatment protected mice from lethal MA15
infection
The results described above raised the possibility that direct
activation of rDCs in the lung or adoptive transfer of activated DCs
to the lung would bypass AM inhibitory function. Signaling through
Toll-like receptors (TLR) results in a series of signaling events that
leads to the induction of an acute inflammatory response. Ligand
binding to TLRs also results in dendritic cell maturation, which is
necessary for the initiation of adaptive immune responses
[46,47,48].PreviousreportsshowedthatPolyI:CorCpGtreatment
protected animal from lethal virus infection, but the mechanism of
protection was not investigated in those studies [49,50]. In
preliminary experiments, we treated mice with ligands for several
TLRs, including poly I:C (TLR3), LPS (TLR4), CpG (TLR9),
R837(TLR7), R848 (TLR7/8), Pam3CSK4 (TLR1/2), and
Pam2CSK4 (TLR2/6). We observed that treatment with poly I:C
(Fig. 5 A) and, to a lesser extent, CpG (data not shown), but not the
other TLR ligands, protected mice from lethal disease. Conse-
quently, additional analyses were performed after treatment with
poly I:C and as a control, LPS since both are widely used to
Macrophages and DCs in SARS-CoV Infection
PLoS Pathogens | www.plospathogens.org 5 October 2009 | Volume 5 | Issue 10 | e1000636Figure 3. MA15-specific T cell responses in the lungs after CL treatment. Mice were treated with CL or PBS, 18–24 h prior to infection with
3610
4 PFU MA15 virus. At the indicated time points, single cell suspension were prepared from lungs, and stimulated with SARS-CoV CD8 (S366, S521
and S1061) or CD4 (N353) T cell peptides for 6 h in the presence of brefeldin A. Frequencies (A) and numbers (B) of total and MA15-specific T cells
(determined by IFN-c intracellular staining) are shown. Data are representative of two to four independent experiments n=5–8 mice/group/time
point. (C) In vivo cytotoxicity assays were performed on day 6 p.i.. Target cells were co-stained with PKH26 and different concentrations of CFSE
(0.1 mMo r1mM) and then incubated with SARS-CoV specific CD8 T cell peptides (0.1 mM CFSE) or in the absence of added peptides (1 mM CFSE) at
37uC for 1 h. 5610
5 target cells from each group were mixed together (1610
6 in total) and transferred i.n. to infected mice. 12 h after transfer, single
cell suspensions were prepared from the lung and examined by flow cytometry. n=3–4 mice/group. Data are representative of two independent
experiments. *P values of ,0.05.
doi:10.1371/journal.ppat.1000636.g003
Macrophages and DCs in SARS-CoV Infection
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aDC activation and T cell proliferation in vitro. Mice were treated with CL or PBS at day 21 prior to infection with 3610
4 PFU MA15. CD86,
CD40, F4/80 and CD200R expression on CD11c
+CD11b
2Siglec F
+ AM (A) and numbers and frequency (B) of AM were determined by flow cytometry.
Black, isotype control; green, naive; blue day 2; red, day 4. yellow, D6. Data are representative of two independent experiments and are the mean
values6SEM (n=7–8 mice/group/time point). *P values of ,0.05. (C) To assess the ability of AM to suppress aDC activation in vitro. AMs were
harvested from BAL (bronchoalveolar) fluid and cultured at 4610
4/well in 96-well dishes for 48 h before use. aDCs were purified from naı ¨ve mice
lungs by FACS sorting. aDCs were cultured in the presence or absence of AMs together at a 1:1 ratio for 24 h at 37uC and subjected to flow
cytometry. Data are representative of four independent experiments. (D) To assess the ability of AM to inhibit T cell proliferation in vitro, single cell
suspensions were prepared from the lungs of naı ¨ve mice or CL-treated MA15-infected mice at day 8 p.i. Cells were incubated on plastic dishes for 2 h
at 37uC, to remove AMs. Naı ¨ve lung cells (4610
5/96-well) were stained with 1 mM CFSE and stimulated with either 2.5 mg/ml Con A or 1 mg/ml soluble
CD3 antibody with or without AMs (4610
4 / 96-well) for 72 h. Solid line, without AMs; gray, with AMs. (E) Total CD8 T cells were purified by
microbeads from lung cells of AM-depleted MA15-infected mice at day 8, stained with 1 mM CFSE and stimulated with splenocytes from naı ¨ve mice or
CD8 T cell-depleted infected lung cells (4610
5/96-well) that were pulsed with SARS-CoV CD8 T cell peptides with or without AM (4610
4 / 96-well) for
72 h. Cells were then subjected to flow cytometry. Solid line, without AMs; gray, with AMs. Data are repesentative of two independent experiments.
doi:10.1371/journal.ppat.1000636.g004
Macrophages and DCs in SARS-CoV Infection
PLoS Pathogens | www.plospathogens.org 7 October 2009 | Volume 5 | Issue 10 | e1000636Figure 5. Protective effects of poly I:C treatment. (A) Mice were treated with 20 mg poly I:C or 5 mg LPS 18–24 h before infection with MA15.
Weight loss and mortality were monitored daily. n=18 in LPS group; 14 mice in Poly I:C group. (B) Lungs were harvested and homogenized and virus
was titered on Vero E6 cells. Viral titers are expressed as PFU/g tissue. (n=4 mice/group/time point). (C) Single cell suspensions were prepared from
lungs of naı ¨ve and treated mice. CD86, CD40. F4/80 and CD200R expression by CD11c
+CD11b
2Siglec F
+ AMs after poly I:C, LPS or no treatment was
determined by flow cytometry. The frequencies of MHC II
+ CD86
+ cell populations are shown. (D and E) Mice were treated with poly I:C or LPS 18–
24 h prior to MA15 infection. At day 7 p.i., single cell suspensions were prepared from lungs, and stimulated with SARS-CoV CD8 (S366, S521 and
S1061) or CD4 (N353) T cell peptides for 6 h in the presence of brefeldin A. Cells were analyzed for IFN-c expression. Frequency (D) and numbers (E) of
virus specific T cells are shown. Data are representative of two independent experiments and are the mean values6SEM (n=5–8 mice/group/time
point). (F) In vivo cytotoxicity assays were performed on day 6 p.i. Target cells were co-stained with PKH26 and different concentrations of CSFE, then
pulsed with/without SARS-CoV specific CD8 T cell peptides, mixed together (1610
6 in total) and transferred i.n. to mice. 12 h after transfer, lung cells
were examined by flow cytometry. n=3–4 mice/group. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1000636.g005
Macrophages and DCs in SARS-CoV Infection
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treated mice lost about 10% of their original weight but quickly
recovered within 7 days. The LPS-treated group (5 mg/mouse), lost
more than 20% of their weight with death occurring in all mice
within 6–7 days. Virus titers were higher at day 5 in the lungs of
these mice compared to mice treated with poly I:C (Fig. 5 B).
Poly I:C, and to a much less extent LPS treatment resulted in
enhanced CD86 and CD40 upregulation on AMs (Fig. 5 C) and
rDCs (Fig. S7). Treatment with both TLR agonists resulted in a
modest increase in F4/80 and a small decrease in CD200R
expression (Fig. 5 C). Consistent with the results obtained after
clodronate treatment (Fig. 3 A), poly I:C treatment resulted in an
earlier and more robust antigen-specific T cell responses than
observed in PBS (Fig. 3 A) or LPS-treated mice (Fig. 5 D, E).
Nearly twenty fold more MA15-specific T cells were detected in
the lungs of poly I:C treated mice compared to LPS recipients at
day 7 p.i. and these cells were functional in in vivo killing assays
(Fig. 5 E and F). To determine whether poly I:C or LPS directly
activated AMs, AMs were isolated and stimulated in vitro with both
agonists. After 24 h stimulation, poly I:C but not LPS treatment
resulted in a pronounced upregulation of CD86 (Fig. 6 A).
Further, treatment with poly I:C but not LPS partially reversed the
ability of AM to inhibit CD8 T cell proliferation after stimulation
with Con A or sCD3 (Fig. 6 B). These results indicate that poly I:C
can abrogate AM inhibitory function both in vivo and in vitro,b y
directly activating AMs and rDCs.
Adoptive transfer of activated BMDCs protected mice
from lethal MA15 infection
Given these results, direct delivery of activated DCs to the lungs
might overcome AM-mediated inhibition. Activated DCs exhibit
an enhanced ability to migrate to DLNs and to stimulate CD8 T
cell proliferation and IFN-c expression [52,53,54,55]. Since AMs
were unable to inhibit costimulatory molecule expression on
previously activated DCs (Fig. 7 A), we next assessed whether
adoptively transferred activated DCs could bypass AM inhibition
and protect mice from a lethal MA15 infection. For this purpose,
bone marrow cells were harvested from naı ¨ve mice, and DCs
selectively cultured by treatment with GM-CSF plus IL-4 for 6
days [56]. BMDCs were then activated with either LPS or poly
I:C, which resulted in enhanced CD86 and MHC class II
expression on BMDCs (Fig. 7 B). As expected, MA15 was unable
to activate these cells. 3610
5 activated or resting BMDCs were
transferred to mice i.n. 18 h prior to infection. Mice that received
BMDCs activated with either poly I:C or LPS were protected from
a fatal outcome, although they still lost about 15% of their body
weight. In marked contrast, recipients of resting BMDC were not
protected (Fig. 7 C). Further, higher virus titers were detected in
the lungs at day 5 mice that received resting BMDC as opposed to
activated BMDC (Fig. 7 D). BMDC migration from the lungs to
DLNs was accelerated by prior activation. More CFSE
+ activated
BMDC than resting BMDC accumulated in the DLNs of recipient
mice (Fig. 8 A and B) and additionally, the total number of cells in
the DLNs was increased dramatically by activated BMDC transfer
(Fig. 8 B). Consistent with enhanced rDC migration to the DLNs,
recipients of activated BMDCs developed more robust CD4 and
CD8 T cell responses in the lungs when compared to those that
received resting BMDC (Fig. 8 C and D). Nearly tenfold more
MA15-specific T cells were detected in the lungs of activated
BMDC compared to resting BMDC recipients at day 7 p.i. and
these cells were functional in in vivo killing assays (Fig. 8 E).
Collectively, these results indicate that adoptive transfer of
activated BMDCs to the lung amplified virus specific T cell
responses, cleared virus earlier and protected mice from lethal
MA15 infection.
Discussion
The pathogenesis of SARS in patients that exhibit more severe
disease is not well understood but includes slow virus clearance
and a prolonged clinical course [19,21,57,58]. The results
presented herein suggest that this severe disease may occur in
part because infected individuals do not mount an appropriate
anti-virus T cell response. Anti-virus CD8 T cells are critical for
virus clearance in mice infected with other pathogens, such as
influenza A virus and LCMV [15,59], so it is not unexpected that
they are necessary for resolution of infection with SARS-CoV.
While lymphopenia is associated with a worse prognosis in SARS
patients [17,18,19], no prior studies, to our knowledge, has shown
that this poor prognosis results, in part, from a sub-optimal CD8 T
cell response. This defect in development of a protective T cell
response occurs because the virus does not reverse the anti-
inflammatory state that is naturally present in the uninfected lung.
These results are consistent with in vitro studies in which the SARS-
CoV is able to infect but can not activate human DCs or
macrophages [22,23,24,25,26,27,28]. This may occur, in part,
because coronaviruses, including SARS-CoV, are ‘‘invisible’’ to
cellular sensors in some cell types [29].
Alveolar macrophages play a central role in maintaining
immunological homeostasis [1,2] and actively suppress the
induction of adaptive immunity through their effects on alveolar
and interstitial DCs and T cells [6,7,8]. Several molecules,
including nitric oxide, TGF-b and CD200R have been implicated
in AM suppressive function. These molecules have either short
half lives or require cell-to-cell contact [1,44,60,61]. Consistent
with this, AMs are separated by a distance of only 0.2–0.5 mm
from rDCs in the lung [10]. Our results also suggest that cell
contact or close proximity to target cells is required, because AMs
were unable to suppress T cell proliferation if separated from
responders by a transwell membrane (Fig. S6 B). In another
mechanism that maintains an anti-inflammatory state in the lungs,
AMs ingest and process innocuous antigen and bacteria before
they can reach and activate rDCs [10]. AM depletion results in
enhanced antigen-presenting function by rDCs [6] and in
increased ability to lyse influenza A virus-infected cells [62].
These reports indicate that countering the quiescent, anti-
inflammatory state of AM is critical for developing a protective
immune response; our results indicate that infection with SARS-
CoV reverses this quiescent state inefficiently. We used three
approaches to support this conclusion. First, pre-treatment of
MA15-infected mice with clodronate depleted AM, resulting in
enhanced activation and migration of rDCs, which in turn led to
the development of a vigorous and protective virus-specific T cell
response in the lung (Fig. 2 and 3). The activation and migration of
rDCs at early times p.i. are critical for the timely initiation of anti-
SARS-CoV T cell responses. Consistent with this, treatment with
clodronate at day 2 p.i. was not protective (Fig. 1), because rDC
migration to the DLNs is largely complete by 48 hours p.i. ((Fig. 2
D) and [12]). Depletion at day 2 p.i. resulted in more severe
disease, suggesting that in SARS-CoV-infected mice, virus-specific
T cells require additional DC stimulation in the lungs, as occurs in
influenza A-infected animals [16].
Second, activation of AMs and rDCs in situ via treatment with
TLR agonists also circumvented the anti-inflammatory state of the
lung. Our results showed that only poly I:C, a TLR3 agonist, and
to a lesser extent CpG, a TLR9 agonist, were able to perform this
function. TLR7 is primarily located on plasmacytoid DCs and the
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PLoS Pathogens | www.plospathogens.org 9 October 2009 | Volume 5 | Issue 10 | e1000636Figure 6. Poly I:C treatment partially reverses AM inhibition of T cell proliferation in vitro. (A) AMs were harvested from BAL fluid, and
cultured at 2.5610
5/well in 24-well dishes for 48 h in the presence of 20 mg/ml poly I:C or 1 mg/ml LPS. Cells were detached and subjected to flow
cytometry. (B) Single cell suspension were prepared from spleens of naı ¨ve mice, stained with 1 mM CFSE and stimulated with either 2.5 mg/ml Con A
or 1 mg/ml soluble CD3 antibody for 72 h in the presence or absence of poly I:C-stimulated AMs from (A). Samples were then subjected to flow
cytometry. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1000636.g006
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PLoS Pathogens | www.plospathogens.org 10 October 2009 | Volume 5 | Issue 10 | e1000636Figure 7. Activation of BMDCs and protective effect of adoptive transfer of activated but not resting BMDCs. (A) LPS (1 mg/ml)
activated BMDCs were co-cultured with AMs harvested from BAL of naı ¨ve mice for 24 h. Phenotype changes were assessed by flow cytometry. AM co-
culture did not inhibit costimulatory molecule expression by previously activated BMDCs. (B) BMDCs were stimulated with 20 mg/ml poly I:C or 1 mg/
ml LPS or MA15 virus (m.o.i.=5) and assayed for CD86 expression. Both poly I:C and LPS activated AM, as measured by CD86 expression. (C) 3610
5
activated or resting BMDCs were transferred by i.n. inoculation 18 h before MA15 infection (3610
4 PFU/mouse). Weight loss and mortality were
monitored daily. n=12 mice in resting BMDC group; 15 mice in activated BMDC group. (D) Lungs were homogenized and virus titered on Vero E6
cells. Viral titers are expressed as PFU/g tissue. (n=4 mice/group).
doi:10.1371/journal.ppat.1000636.g007
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PLoS Pathogens | www.plospathogens.org 11 October 2009 | Volume 5 | Issue 10 | e1000636Figure 8. Enhanced DC migration to DLN and MA15-specific T cell response after. transfer of activated but not resting BMDCs. (A)
Activated or resting BMDCs were stained with 1 mM CFSE, and adoptively transferred to mice. After 18 h, mice were infected with 3610
4 PFU MA15.
Single cell suspensions were prepared from DLNs and CFSE
+ cells were identified by flow cytometry. Total CFSE
+ cells and LN cells numbers are
shown in (B). Activation of BMDC enhanced migration to DLN and also increased total DLN cellularity. Data are representative of two independent
experiments and are the mean values6SEM (n=6–8 mice/group/time point). (C and D) Activated or resting BMDCs were transferred 18–24 h prior to
infection with MA15. At day 7 p.i., single cell suspensions were prepared from lungs, and stimulated with SARS-CoV CD8 (S366, S521 and S1061) or
CD4 (N353) T cell peptides for 6 h in the presence of brefeldin. Cells were analyzed for IFN-c expression A. Frequency (C) and numbers (D) of MA15-
specific T cells are shown. Data are representative of two independent experiments and are the mean values6SEM (n=6–7 mice/group/time point).
(E) In vivo cytotoxicity assays were performed on day 6 p.i. Target cells were co-stained with PKH26 and different concentrations of CSFE, pulsed with/
without SARS-CoV specific CD8 T cell peptides, mixed together (1610
6 in total) and transferred i.n. to mice. 12 h after transfer, lung cells were
examined by flow cytometry. n=3–4 mice/group. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1000636.g008
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cells was insufficient to induce a protective immune response. Poly
I:C, which activated AMs and rDC in vivo (Fig. 5 C and S7) and in
vitro (Fig. 6 A), protected animals from lethal MA15 infection. The
ability of poly I:C to stimulate rDC activation and migration has
been described previously [12], and is likely to explain its
protective ability. It should be noted that poly I:C treatment also
induced type 1 IFN expression in the lung. This may also have
contributed to the protective effect of poly I:C, but this is not likely
to be the major effect because SARS-CoV is only modestly
sensitive to IFN treatment of cultured cells or of mice [63,64]. In
addition, CL treatment did not induce type 1 IFN in the lungs,
showing that IFN induction is not required for protection (data not
shown).
LPS, which is a TLR4 agonist, was unable to protect mice from
lethal disease. We considered the possibility that LPS might have
toxic effects unrelated to TLR4 binding, but treatment with
monophosphoryl lipid A (MPLA), a derivative of LPS that is a
TLR4 agonist but is less toxic [65,66], was also not protective (data
not shown). Our results are consistent with a recent study that
showed that TLR4 ligation contributed to worse outcomes in
several models of lung injury [67]. TLR4 ligation, in the absence
of treatment with specific agonists, did not contribute to worsened
disease in MA15-infected BALB/c mice since infection of
TLR4
2/2 BALB/c mice did not result in significant differences
in clinical disease when compared to wild type BALB/c mice (data
not shown).
Third, we showed that adoptive transfer of activated but not
resting BMDCs bypassed AM-mediated suppression and protected
mice from lethal disease (Fig. 7). While DC maturation makes
these cells the most potent in antigen presentation in an animal, it
also results in the loss of ability to take up antigen. However,
antigen macropinocytosis is transiently stimulated after activation
[52], possibly explaining how transferred BMDC could acquire
SARS-CoV antigen for presentation to T cells in the DLNs.
Alternatively, mature DCs are able to uptake antigen for cross-
presentation [68]. Activated BMDCs preferentially migrated to
the DLNs (Fig. 8 A and B) and initiated a protective T cell
response in the lungs (Fig. 8 C–E). This transfer was successful
because inhibitory AMs cannot reverse prior rDC activation (Fig. 7
A). All of these three experimental interventions resulted in
enhanced rDC migration to the DLNs, enhanced MA15-specific
T cell responses at the site of infection, the lungs, and improved
outcomes.
It is notable that virus-specific T cells are also critical for virus
clearance in C57BL/6 mice, which are resistant to MA15
infection. Six week old mice deficient in recombination activating
enzyme activity 1 (RAG1
2/2) on a C57Bl/6 background do not
clear virus when measured at 9 days [69] or even 21 days p.i. (data
not shown), yet remain completely asymptomatic. On the other
hand, mice with Severe Combined Immunodeficiency Syndrome
(SCID) on a BALB/c background, which, like RAG1
2/2 mice,
are genetically unable to mount a T cell response, develop clinical
disease that is more severe than that observed in wild type BALB/
c mice. All SCID mice succumb to the infection (data not shown),
compared to a 60–70% mortality rate in BALB/c mice that are
infected with the same dosage of virus (Fig. 1 A). Collectively, these
results show that an optimal T cell response is required for virus
clearance but that strain-specific components of the initial immune
response, not yet defined, are critical for preventing clinical disease
in resistant strains.
An outstanding question is why SARS-CoV does not activate
AMs and rDCs in BALB/c mice. As described above, SARS-CoV
does not efficiently activate human DCs or macrophages. We have
also shown that MA15 does not efficiently induce costimulatory
molecule upregulation on murine rDCs or AM in vivo and/or in
vitro (Fig. 2 C, 4 A and S2). However, while most viruses have
mechanisms to evade host recognition sensors, they still efficiently
induce an immune response. For example, successful resolution of
influenza A virus infections requires activation of immune
responses via TLR7, RIG-I and NLR (NOD-like receptors)
inflammasome pathways [70], even though influenza A virus
encodes an immune-evading protein, nsp1 [71]. HSV, lympho-
cytic choriomeningitis virus, hepatitis C virus, RSV and human
cytomegalovirus are recognized via TLR2-dependent mechanisms
while the RSV F protein activates cells via a TLR4-dependent
mechanism [37]. Some viruses, such as vaccinia virus, directly
inhibit TLR expression, confirming the importance of these
molecules in virus recognition by the host [72]. TLR signaling is
also important for SARS-CoV recognition by the innate immune
system, since C57BL/6 mice, which are very resistant to the virus,
become susceptible when MyD88 is genetically deleted [69]. The
precise TLR or other receptor required for protection in C57BL/6
mice is not known at present. Why this same pathway is not
efficiently induced in BALB/c mice after MA15 infection will be
an area of future investigation.
In conclusion, we have shown that lethal disease in mice
infected with a mouse-adapted strain of SARS-CoV (MA15) is
correlated with a lack of activation of AMs and rDCs. Further,
lethal disease can be prevented if AMs with anti-inflammatory
properties are depleted from lungs prior to infection. Depletion
results in enhanced DC recruitment to the lung and accelerated
migration to DLN, and a more vigorous anti-SARS-CoV T cell
response. Treatment with TLR agonists to activate AMs and rDCs
or transfer of activated BMDCs also prevents a lethal outcome.
Together, these results demonstrate that SARS-CoV, by ‘‘hiding’’
from the immune system, uses a novel mechanism to evade
immune recognition in mice. The pathogenesis of SARS in
humans may involve similar stealth mechanisms.
Materials and Methods
Mice, cells and virus
Pathogen-free BALB/c mice were purchased from the National
Cancer Institute (Frederick, MD). Mice were maintained in the
animal care facility at the University of Iowa. Animal studies were
approved by the University of Iowa Animal Care and Use
Committee. African Green monkey kidney-derived Vero E6 cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO, Grand Island, NY) supplemented with 25 mM HEPES
and 10% fetal bovine serum (FBS) (Atlas Biologicals, Fort Collins,
CO). Mouse-adapted SARS-CoV (MA15) was a kind gift from Dr.
Kanta Subbarao (N.I.H., Bethesda, Maryland) [30]. Virus was
passaged once on Vero E6 cells.
Virus infection and titration
Mice were lightly anesthetized with isoflurane and infected
intranasally (i.n.) with 3610
4 PFU of MA15 virus in 25 mlo f
DMEM medium. Mice were monitored for weight loss and
mortality daily. All work with MA15 virus was conducted in the
University of Iowa Biosafety level 3 (BSL3) Laboratory Core
Facility. To obtain lungs for virus titers, animals were sacrificed at
the indicated time points post-infection (p.i.) and lungs were
removed into phosphate buffered saline (PBS). Tissues were
homogenized using a manual homogenizer, and titered on Vero
E6 cells. For plaque assays, cells were fixed with 10%
formaldehyde and stained with crystal violet three days post-
infection. Viral titers are expressed as PFU/g tissue.
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A peptide library, covering all 4 structural proteins of SARS-
CoV was provided by BEI Resources (Manassas, VA). Virus-
specific peptides were synthesized by BioSynthesis Inc. (Lewisville,
TX). TLR agonists poly I:C, Monophosphoryl Lipid A (MPLA),
CpG, Imidazoquinoline compound (R837 and R848), Pam3CSK4
and Pam2CSK4 were purchased from Invivogen (San Diego, CA).
LPS was purchased from Alexis Biochemicals (Farmingdale, NY).
Clodronate-liposome treatment
Alveolar macrophage depletion was performed by treatment
with liposomes containing dichloromethylene bisphosphonate
(clodronate). Clodronate was a gift from Roche Diagnostics
GmbH (Mannheim, Germany), and it was encapsulated in
liposomes as described earlier [9,33]. At the indicated times, mice
were anesthetized by intraperitoneal injection of 2% avertin and
administered 75 ml of clodronate liposomes, or PBS i.n.
Histology
Animals were anesthetized and transcardially perfused with PBS
followed by zinc formalin. Lungs were removed, fixed in zinc
formalin, and paraffin embedded. Sections were stained with
hematoxylin and eosin.
Lung cells and draining lymph node cells preparation
Mice were anaesthetized with 100 ml pentobarbital (50 mg/ml,
Lundbeck Inc., Deerfield, IL) at the indicated time points. The
lung vascular bed was flushed via the right ventricle with 5 ml PBS
to eliminate any blood and lungs and draining lymph nodes were
then removed. Lungs were cut into small pieces and digested in
HBSS buffer containing 2% FCS, 25 mM HEPES, 1 mg/ml
Collagenase D (Roche, Indianapolis, IN) and 0.1 mg/ml DNase
(Roche) for 30 min at RT. Lymph nodes were minced and pressed
though a wire screen. Particulate matter was removed with a
70 mm nylon filter to obtain single-cell suspensions. Cells were
enumerated by 0.2% trypan blue exclusion.
In situ CFSE staining
CFSE (Molecular Probes, Eugene, OR) was dissolved at 25 mM
in DMSO stored at 220uC until use. The CFSE stock solution
was diluted in DMEM media to a concentration of 8 mM and
then administered i.n. (50 ml/mouse) following anesthesia with
isoflurane [12].
Flow cytometry
The following monoclonal antibodies were used for these
studies: rat anti-mouse CD3 (145-2C11), rat anti-mouse CD4
(RM4-5), rat anti-mouse CD8b (53-6.7), rat anti-mouse CD11b
(M1/70), hamster anti-mouse CD11c (HL3), rat anti-mouse
CD16/32 (2.4G2), rat anti-mouse Siglec F (E50-2440), mouse
anti-mouse I-A
d (AMS-32.1), all from BD Bioscience (San Diego,
CA); rat anti-mouse IFN-c (XMG1.2), anti-mouse F4/80 (BM8),
rat anti-mouse CD40 (1C10), all from eBioscience (San Diego,
CA); rat anti-mouse CD43 (1B11, Biolegend, San Diego, CA); rat
anti-mouse CD200R (OX-110, Serotec, Raleigh, NC).
For surface staining, 10
6 cells were blocked with 1 mg anti-
CD16/32 antibody and 1% rat serum, stained with the indicated
antibodies, and then fixed using Cytofix Solution (BD Biosciences).
For intracellular cytokine staining (ICS), cells were cultured at
1610
6 per 96-well at 37uC for 6 h or the indicated time period in
the presence of brefeldin A (BD Biosciences). Cells were then
labeled with surface antibodies, fixed/permeabilized with Cytofix/
Cytoperm Solution (BD Biosciences) and labeled with anti-IFN-c
antibody. All flow cytometry data were acquired on a BD
FACSCalibur or an LSR II (BD Biosciences) flow cytometer with
CellQuest (BD Biosciences) and were analyzed using FlowJo
software (Tree Star, Inc. Ash, OR).
In vivo cytotoxicity assay
In vivo cytotoxicity assays were performed on day 6 after MA15
infection, as previously described [73]. Briefly, splenocytes from
naive mice were costained with PKH26 (Sigma-Aldrich, St. Louis,
MO) and either 1 mM or 100 nM CFSE (Molecular Probes,
Eugene, OR). Labeled cells were then pulsed with the indicated
peptides (3 mM) at 37uC for 1 h and 5610
5 cells from each group
were mixed together (1610
6 cells in total). Cells were transferred
i.n. into mice and at 12 h after transfer, total lung cells were
isolated. Target cells were distinguished from host cells on the basis
of PKH26 staining and from each other on CFSE staining. After
gating on PKH26
+ cells, the percentage killing was calculated as
previously described [73].
Alveolar macrophage preparation and in vitro T cell co-
culture
AMs were obtained from uninfected lungs as previously
described [74]. Briefly, lungs were inflated with warm PBS
containing 0.2% BSA and 12 mM lignocaine (Sigma-Aldrich, St.
Louis, MO) via cannulation of the trachea, and were lavaged at
least 6 times. Cells were collected by centrifugation, resuspended
in RPMI 1640 (Gibco, Grand Island, NY) containing 10% FCS
(Atlanta, Lawrenceville, GA) and cultured at 4610
4 in each 96-
well for 48 h before use in the presence or absence of stimulators
[75].
To demonstrate inhibition of polyclonal T cell proliferation,
4610
5 splenocytes or lung cells (after AM-depletion by attachment
to plates for 2 h at 37uC) were labeled with 1 mM CFSE and
added to wells, stimulated with 2.5 mg/ml Con A (Sigma) or 1 mg/
ml soluble CD3 (eBioscience) and cultured with AMs at a ratio of
10:1 for 72 h. For inhibition of virus-specific CD8 T cell
proliferation, lung CD8 T cells were purified from AM-depleted,
MA15-infected animals at day 8 p.i. using CD8 Microbeads
(Miltenyi Biotec, Cologne, Germany) at day 8. Splenocytes pulsed
with 1 mM peptides or CD8 T cell-depleted lung cells were added
as APCs and cultured with AMs at a ratio of 10:1 for 72 h. Cells
were then harvested, stained with antibodies and subjected to flow
cytometric analysis.
Purification of lung DCs
aDC population were purified from the lungs of naı ¨ve BALB/c
mice by FACS sorting based on their expression of CD11c
+MHC
II
+CD11b
2 (Fig. S1) and enriched to about 80% purity.
Generation of BM-derived DCs and adoptive transfer
Bone marrow-derived DCs (BMDC) were generated as
previously described [56]. Briefly, red blood cell-depleted BM
cells were plated at a density of 1610
6/ml in RP10 (RPMI with
10% fetal calf serum, 1.0 mM HEPES, 0.2 mM L-glutamine,
0.05 mM gentamicin sulfate, 1% penicillin- streptomycin, 1 mM
sodium pyruvate, and 0.02 mM 2-mercaptoethanol) supplemented
with 1,000 U/ml recombinant granulocyte-macrophage colony
stimulating factor (BD Pharmingen) and 50 U/ml recombinant
interleukin-4 (eBioscience). Cells were incubated for 6 days, with
75% medium replacement every 2 days. At day 6, BMDCs were
stimulated with or without 20 mg/ml Poly I:C or 1 mg/ml LPS for
18–24 h. CD11c microbeads and a Miltenyi autoMACS magnetic
cell sorter (Miltenyi Biotec, Cologne, Germany) were used to
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+ DCs. Purity was confirmed by flow cytometry.
BALB/c mice were lightly anesthetized with isoflurane and 3610
5
BMDCs in 75 ml PBS were adoptively transfer i.n. 18 h before
MA15 infection.
Statistical analysis
A Student’s t test was used to analyze differences in mean values
between groups. All results are expressed as means6standard
errors of the means (SEM). P values of ,0.05 were considered
statistically significant.
Supporting Information
Figure S1 Gating strategy for DC and AM. (A) Gating strategy
for aDCs, iDCs and AMs. Lungs were harvested, digested with
collagenase, and examined for aDCs, iDCs and AMs populations
by flow cytometry gating on the following markers: iDCs,
CD11c
+CD11b
+MHC II
+; aDCs, CD11c
+CD11b
2MHC II
+;
AM, CD11c
+CD11b
2Siglec F
+. (B) Gating strategy for migratory
DCs. Mice were treated with 50 ml 8 mM CFSE i.n. 6 h after
CFSE instillation, single cell suspensions were prepared from lung
DLNs and gated for CD11c expression by flow cytometry.
Representative side scatter versus CFSE staining of CD11c
+ gated
cells is shown.
Found at: doi:10.1371/journal.ppat.1000636.s001 (2.30 MB TIF)
Figure S2 MA15 infection did not activate AM in vitro. AMs
were harvested from BAL fluid and infected with MA15
(multiplicity of infection=5) for 24 h Expression of CD86 were
determined by flow cytometry. Data are representative of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000636.s002 (0.42 MB TIF)
Figure S3 Depletion of alveolar macrophages by clodronate-
liposomes. Mice were treated with 75 ml clodronate-liposomes, or
PBS i.n. 24 or 48 h after treatment, lungs were examined by flow
cytometry for frequency (A) and total numbers (B) of AM
(CD11c
+CD11b
2SiglecF
+). Data are representative of four
independent experiments and are the mean values6SEM (n=8
mice/group/time point).
Found at: doi:10.1371/journal.ppat.1000636.s003 (0.71 MB TIF)
Figure S4 Activation of T cells during MA15 infection. Mice
treated with CL or PBS were infected with 3610
4 PFU MA15
virus. At the indicated time points, single cell suspension were
prepared from lungs and the expression of CD43 (mAb 1B11),
CD8 and CD4 determined by flow cytometry. Frequency and
numbers of CD8 (A) and CD4 (B) T cells are shown. Data are
representative of two independent experiments and are the mean
values6SEM (n=6–8 mice/group/time point).
Found at: doi:10.1371/journal.ppat.1000636.s004 (1.58 MB TIF)
Figure S5 F4/80 and CD200R expression on alveolar and
peritoneal macrophages. AMs were harvested from BAL fluid. To
obtain peritoneal macrophages, mice were inoculated with 2 ml 3%
thioglycolate media 4 days before peritoneal lavage. Cells were
examined by flow cytometry for expression of F4/80 and CD200R
(solid line). Gray, isotype control. Change of Mean fluorescence
intensity(DMFI)=MFItest2MFIiso.DMFIofF4/80expression:PM
(87.4)vsAM(13.4), DMFIofCD200R expression:PM(39.3)vs AM
(115). Data are representative of three independent experiments.
Found at: doi:10.1371/journal.ppat.1000636.s005 (0.48 MB TIF)
Figure S6 Cytokine expression after AM and T cell co-culture
and requirement for direct AM-T cell contact for inhibition of cell
proliferation. (A) AMs were harvested from bronchoalveolar
lavage fluid (BALF) and cultured at 4610
4 in each 96-well. AM-
depleted MA15-infected lung cells were stimulated with SARS-
CoV CD8 (S366, S521 and S1061) peptides for 6 h in the
presence or absence AMs. Brefeldin A was added during the last
2 h of co-culture. IFN-c expression was determined by intracel-
lular staining. Data are representative of three independent
experiments. (B) AMs were harvested from BAL fluid and cultured
at 2.5610
5 /well in 24-well dishes for 48 h before use. Single cell
suspension were prepared from spleens of naı ¨ve mice, stained with
1 mM CFSE, stimulated with either 2.5 mg/ml Con A or 1 mg/ml
soluble CD3 antibody for 72 h above a semi-membrane, and
subjected to flow cytometry. Data are representative of two
independent experiments.
Found at: doi:10.1371/journal.ppat.1000636.s006 (0.85 MB TIF)
Figure S7 rDC phenotypic changes after poly I:C and LPS
treatment in vivo. Mice were treated with 20 mg poly I:C or 5 mg
LPS for 18–24 h. Single cell suspension were prepared from lungs.
CD86 and CD40 expression on aDCs (CD11c
+CD11b
2MHC II
+)
and iDCs (CD11c
+CD11b
+MHC II
+) were determined by flow
cytometry. The frequencies of MHC II
highCD86
+ or CD40
+MHC
II
high populations are shown. Data are representative of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000636.s007 (1.19 MB TIF)
Table S1 Bio-plex assay for cytokines and chemokines production
during MA15 infection. Mice were treated with either PBS or CL
24 h before MA15 infection. Lungs were harvested at day 0, day 2
and day 4 p.i. After homogenization and ultraviolet light inactivation,
samples were analyzed for cytokine and chemokine expression using
a Bio-Plex cytometric bead assay and a Luminex 200 luminometer
(Bio-Rad). The concentration of cytokines and chemockines was
expressed as pg/ml lung homogenate. *P values of ,0.05.
Found at: doi:10.1371/journal.ppat.1000636.s008 (0.04 MB
DOC)
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